Formulation development and glycosylation inhibition assay


  • KULKARNI AS Department of Pharmacognosy, Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Pune, Maharashtra, India.
  • BHUJBAL SS Department of Pharmacognosy, Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Pune, Maharashtra, India.



Alginate microspheres,, Hemoglobin,, Glycosylation,, Quercetin


Objective: The objective of the present study was to formulate, evaluate alginate microspheres of curcumin, and to investigate the inhibitory effect on glycosylated hemoglobin.

Methods: All formulations were prepared by an ionotropic gelation technique using sodium alginate as a polymer and calcium chloride as a crosslinker in varying concentrations. The formulation batches (F1–F6) were evaluated for physical properties such as compatibility studies, percentage entrapment efficiency (%EE), microsphere yield, particle size, and polydispersity index. In vitro, drug release was studied and surface morphology was characterized by scanning electron microscopy.

Results: The microspheres showed %EE, microsphere yield, particle size in the ranges of 44.86%–84.24%, 43.05%–81.4%, and 352–559 μm, respectively. In vitro, drug release and release kinetics showed that the developed curcumin microspheres system is a promising delivery system for controlled drug release. Scanning electron micrographs indicate porous and rough surface. The inhibitory properties of curcumin and microspheres (F4) on glycosylation formation were investigated in hemoglobin using quercetin as standard. The decreased in hemoglobin concentration after incubation of hemoglobin with a graded concentration of glucose over a specified time was used as an index for in vitro human hemoglobin glycosylation assay. Glycosylation inhibition was about 75% for standard quercetin, 60% for curcumin microspheres, and 38.74% for curcumin suspension occurred after 72 h.

Conclusion: From these results, it can be concluded that curcumin in microsphere formulation has better therapeutic potential and could prove to be useful in the development of antidiabetic formulation.


Peacock I. Glycosylated haemoglobin: Measurement and clinical use. J Clin Pathol 1984;37:841-51.

Shapiro R, McManus MJ, Zalut C, Bunn HF. Sites of nonenzymatic glycosylation of human hemoglobin A. J Biol Chem 1980;255:3120-7.

Nawale RB, Mourya VK, Bhise SB. Non-enzymatic glycation of proteins: A cause for complications in diabetes. Indian J Biochem Biophys 2006;43:337-44.

Thorpe SR, Baynes JW. Maillard reaction products in tissue proteins: New products and new perspectives. Amino Acids 2003;25:275-81.

Adisa RA, Oke J, Olomu SA, Olorunsogo O. Inhibition of human haemoglobin glycosylation by flavonoid containing leaf extract of Cnestis ferruginea. J Cameroon Acad Sci 2004;4:351-9.

Arun N, Nalini N. Efficacy of turmeric on blood sugar and polyol pathway in diabetic albino rats. Plant Foods Hum Nutr 2002;57:41-52.

Seo KI, Choi MS, Jung UJ, Kim HJ, Yeo J, Jeon SM, et al. Effect of curcumin supplementation on blood glucose, plasma insulin, and glucose homeostasis related enzyme activities in diabetic db/db mice. Mol Nutr Food Res 2008;52:995-1004.

Duggi S, Handral HK, Handral RA, Tulsianand G, Shruthi SD. Turmeric: Nature’s precious medicine. Asian J Pharm Clin Res 2013;6:10-6.

Purpura M, Lowery RP, Wilson JM, Mannan H, Münch G, Razmovski- Naumovski V. Analysis of different innovative formulations of curcumin for improved relative oral bioavailability in human subjects. Eur J Nutr 2018;57:929-38.

Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: Problems and promises. Mol Pharm 2007;4:807-18.

Wang S, Tan M, Zhong Z, Chen M, Wang Y. Nanotechnologies for curcumin: An ancient puzzler meets modern solutions. J Nanomater 2011;2011:1-8.

Szekalska M, Pucilowska A, Szymanska E, Ciosek P, Winnicka K. Alginate: Current use and future perspectives in pharmaceutical and biomedical applications. Int J Polym Sci 2016;2016:1-17.

Dash S, Murthy PN, Nath L, Chowdhury P. Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol Pharm 2010;67:217-23.

Asgary S, Naderi G, Sarrafzadegan N, Ghassemi N, Boshtam M, Rafie M, et al. Anti-oxidant effect of flavonoids on hemoglobin glycosylation. Pharm Acta Helv 1999;73:223-6.

Drabkin DL, Austin JH. Spectrophotomeric studies: Spectrophotometric constant for common hemoglobin derivatives in human, dogs and rabbit blood. J Biol Chem 1932;98:719.

Parker KM, England JD, Da Costa J, Hess RL, Goldstein DE. Improved colorimetric assay for glycosylated hemoglobin. Clin Chem 1981;27:669-72.

Hariyadi DM, Hendradi E, Purwanti T, Fadil F, Ramadani C. Effect of cross linking agent and polymer on the characteristics of ovalbumin loaded alginate microspheres. Int J Pharm Pharm Sci 2014;6:469-74.

Madhavi C, Kumara Babu P, Maruthi Y, Parandhama A, Shreenath Reddy O, Rao KC, et al. Sodium alginate – Locust bean gum ipn hydrogel beads for the controlled delivery of nimesulide-anti-inflammatory drug. Int J Pharm Pharm Sci 2017;9:245-52.

Voo WP, Chien CW, Islam A, Tey BT, Chan ES. Calcium alginate hydrogel beads with high stiffness and extended dissolution behaviour. Eur Polym J 2016;75:343-53.

Mazumder R, Nath K, Haque A, Maity T, Choudhury PK, Shrestha B, et al. Formulation and in vitro evaluation of natural polymers based microspheres for colonic drug delivery. Int J Pharm Pharm Sci 2010;2:211-9.



How to Cite

KULKARNI AS, and BHUJBAL SS. “The ALGINATE MICROSPHERES CONTAINING CURCUMIN: PREPARATION, CHARACTERIZATION, AND IN VITRO HUMAN HAEMOGLOBIN GLYCOSYLATION ASSAY: Formulation Development and Glycosylation Inhibition Assay”. Asian Journal of Pharmaceutical and Clinical Research, vol. 12, no. 7, July 2019, pp. 221-5, doi:10.22159/ajpcr.2019.v12i7.33770.



Original Article(s)